Sponsor: Volastra
Sponsor Study ID: SOVI-2302
Study Title: A Phase 1b Dose Optimization Study of Sovilnesib (An Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer
CTO #: 104007
NCT Number: NCT04293094
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary
Study Objectives: To compare the safety, tolerability, and preliminary efficacy of sovilnesib at selected dose levels (DLs) to determine the Recommended Phase 2 Dose (RP2D). To further assess the efficacy of sovilnesib. To characterize the pharmacokinetics (PK) of sovilnesib.